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This is a pharmaeconomic study to assess the impact of diﬀerent, cost-speciﬁc pharmacological strategies on the recurrence rate
of prescriptions in the treatment of cold symptoms. Data were obtained from a prospective cohort study reporting individual
prescriptions histories of subjects experiencing cold symptoms, obtained by a stratiﬁed random sample of 316 subjects, clustered
into 139 Italian families, followed up for 40months. Costs of homeopathic and allopathic treatments were recorded within each
prescription. A Cox proportional hazards model with random eﬀects was exploited to regress time elapsed between subsequent
prescriptions over the relative diﬀerence between homeopathic- and allopathic-related costs, adjusting for age and gender and
accounting for unobserved individual heterogeneity. Relative risks of event (prescription) re-occurrence have been estimated.
The recurrence rate of prescriptions raise when allopathic strategies are preferred to homeopathic alternatives. No signiﬁcant
diﬀerences were observed between gender groups, while age was marginally signiﬁcant. Inter-subjects heterogeneity was not
signiﬁcant.
1.Introduction
Studies on cost-eﬀectiveness of homeopathy aim to show
that homeopathic cure strategies are less expensive than
conventional medicine and that health costs could be
lowered if mainstream therapies would be replaced by
homeopathy. For example [1], a decrease in admissions to
hospital outpatient services and pharmaceutical utilization
has been reported when complementary medicine was used
in conjunction with conventional medicine. However, some
data have suggested that including complementary medicine
may increase overall costs for adults as it is used as an “add
on” rather than a replacement [2].
Thesestudiesareoftencarriedoutbycomparingmedical
eﬀectiveness, quality of life and costs resulting from patients
who undergo a homeopathic treatment, to the outcomes
fromacontrolgroup,typicallytreatedbyconventionalmain-
stream medicine. Although cost data should be collected
prospectively, as a part of a pragmatic clinical trial [3–
6], these studies are time-consuming and quite expensive.
As a result, the literature on the cost-eﬀectiveness of
homeopathy is often based either on post-hoc analysis of
past prospective studies [7] or on retrospective studies [8]o r
comparingthecostsofhomeopathictreatmentsinagroupto
the (estimated) cost of conventional drugs which otherwise
would be prescribed for the observed subjects [9].
Fewer are prospective cohort studies that compare cost-
eﬀectiveness of allopathic and homeopathic treatments. The
outcomes research by Witt et al. [10] for example, is
based on a prospective, non-randomized, open cohort study,
where subjects are approached at the doctor’s practice and
thus already made their own choice of therapy (purely
allopathic or purely homeopathic). The authors’ conclusion
was that patients seeking homeopathic treatment had a
better outcome (in terms of severity of symptoms) overall
compared with patients on conventional treatment, whereas
total costs in both groups were similar.
In everyday medical practice, though, patients’ choices
are seldom consistent with a pure pharmacological strategy.
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treatment, in conjunction with conventional medicine.
Moreover, some subjects who started a pure allopathic
therapy may change their mind and turn to homeopathic
strategies, while others unsatisﬁed with homeopathy may
decide to go back to allopathic strategies. In the case of such
time-varying, mixed strategies, it is diﬃcult to ascertain if
patients’ beneﬁts are associated with a kind of therapy and
its cost. Observational studies that account for heterogeneity
in patients’ behavior are, nevertheless, of special interest
to insurers and medical service providers. However, to our
knowledge, no study has provided results on both the
outcome and costs of treatment, when subjects are left free
to change their pharmacological strategy, during the follow
up.
In this article, the outcome of interest is the temporal
interval between any two subsequent prescriptions involving
either allopathic or homeopathic or mixing allopathic and
homeopathic treatments, during a follow up of subjects who
experience cold symptoms. The rate at which prescriptions
occur within the subject’s history is important to evaluate
the eﬀectiveness of a treatment. For example, long intervals
between consecutive prescriptions may indicate that, while
the subject’s pharmacological strategy stops suddenly the
symptoms, it does not avoid the re-occurrence of the same
symptoms after a long period of time. Conversely, short
intervalsfollowedbylongintervalsmayindicate,ononeside,
that the treatment involves a number of prescriptions to have
an appreciable impact on the subject, and that, on the other
side, the strategy of choice reduces the risk of re-occurrences
of symptoms.
For each inter-prescription interval, we have considered
the cumulative cost of both homeopathic and allopathic
treatments charged to each subject up to the date of the latest
prescription. The relative diﬀerence between the (cumu-
lative) costs attributable to the allopathic treatments and
those relating to the homeopathic strategy was computed
to summarize the subject-speciﬁc, time-varying economic
relevance of one strategy over the other one, or, in other
words, an indicator of the ﬁnancial weight given by a subject
to each strategy during the follow up.
Regressing the observed inter-prescription intervals on
this indicator can help testing the impact that the ﬁnancial
eﬀort for a speciﬁc pharmacological history has on the rate
of prescriptions occurrences. We modeled the rate at which
prescriptions occurred by exploiting a Cox proportional
hazards model [11]. Under the simplifying assumption that
the rate at which precriptions occurr varies proportionally
with the economic relevance of a pharmacological strategy,
this approach allows to estimate the eﬀect of a treatment’s
relative cost on the rate of medical interventions. We also
extended this analysis by including a random eﬀect [12]a n d
thereby adjusting for the presence of possibly unobserved
confounding factors.
Our pharmacoeconomic study has been carried out by
prospectively collecting the biographies (dates and costs
of prescriptions) of 316 subjects belonging to 139 Italian
families, drawn from the list of Italian journalists’ families
by a stratiﬁed random sampling design and followed up for
40 months. Among these, only 82 biographies reported two
or more cold-related prescriptions and were included in the
analysis.
2.MaterialsandMethods
2.1. Data. CASAGIT is the journalists’ health insurance
company in Italy. This company allows for reimbursement of
bothallopathicdrugsandhomeophaticprescriptionsbought
by its customers and their families (the study population).
A stratiﬁed sampling scheme was adopted to draw a sample
of 139 families (316 patients) for follow up. Sample size
was determined according to the available funds for the
present project. Stratiﬁcation variables included the average
age of the family, residence and family size. All the subjects
within each family were followed up during the period June
2002 to October 2005, after giving written informed consent.
The study was compliant with relevant data protection
laws.
For each subject, the dates of the prescriptions were
recorded.Thetreatmentsprescribedeachtimewereclustered
into two classes, namely conventional or homeopathic,
and the relating costs recorded. Homeopathic treatments
included purely homeopathic, antroposophical and homeo-
tossicological remedies. In keeping with other studies [10],
total costs of homeopathic and allopathic treatments were
similar.
Gender and age were also included in the individual
proﬁle. About 55% of the sampled subjects were females.
Figures 1 and 2 display the age distribution of the sample.
We notice that the age classes between 20 and 30years
contain a few subjects, as expected when a journalist’s
family is chosen as sampling unit. Only 151 subjects (among
the 316 included in the sample) experienced cold-related
symptoms (common cold, inﬂuenza and para-inﬂuenza),
without co-morbidities such as chronic pulmonary dis-
eases or chronic cardiovascular diseases, as reported by
the family GP. Among these, only the 82 subjects who,
during the follow up, asked for reimbursement of two or
more prescriptions were considered for further statistical
analysis, as we are interested in re-occurrence of prescrip-
tions.
Figure 3 depicts the intervals between any two subse-
quent prescriptions within each of the 82 subjects, during
the follow up. The dots in the picture represent the 231
observed prescriptions: of these, 67 (29%) were purely
allopathic, 27 (12%) were purely homeopathic, while the
remaining prescriptions involved a mixture of homeopathic
and allopathic pharmacological treatments.
The large variability of the lengths of these intervals
is apparent, showing diﬀerent typical patterns of events.
Speciﬁcally, some subjects experience a number of pre-
scriptions occurring in a short period of time, hence
separatedbyshortintervals,andnoprescriptionsafterwards.
Others exhibit single-event occurrences separated by longer
intervals. Finally, a part of the sample shows mixed patterns,
featuring short inter-prescription intervals, followed by
longer intervals and, conversely, distant event occurrences
followed by short intervals.Evidence-Based Complementary and Alternative Medicine 3
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Figure 1: Age distribution of the 174 females in the study sample.
2.2. Statistical Analysis. The main goal of the statistical
analysis exploited in this study was to test the impact of
the economic relevance of allopathic versus homeopathic
strategies on the prescriptions patterns experienced by the
observed subjects.
For each subject, the number of days between any two
prescriptions was calculated. We also evaluated the cumu-
lative costs of allopathic and homeopathic prescriptions
occurred up to the right end of each interval. The relative
diﬀerence between allopathic and homeopathic cumulative
costs was calculated for each interval: this cost-incidence
index takes the value of −1f o ras u b j e c tf o l l o w i n gap u r e
homeopathic therapy up to the date relating to the right end
of the interval and +1, in case of a pure allopathic therapy.
When the costs of the two strategies are equal, the index
takes the value 0. Negative (positive) values indicate that the
cumulative homeopathic costs were larger (lower) than their
allopathic counterpart. This index is a continuous measure
of cumulative costs incidence that avoids a naive repartition
of subjects into three groups with a debatable homogeneity:
(i) receiving only allopathy, (ii) receiving only homeopathy
and (iii) receiving both.
A Cox proportional hazards model [11]w a sﬁ t t e dt o
the durations between prescriptions by using the cumulative
relative diﬀerence between allopathic and homeopathic
cumulative costs as the main covariate, and simultaneously
adjusting for age and gender. After testing the proportional
hazards assumption [12] relative risks were estimated with
respect to subjects whose cost-incidence index was equal to 0
(baseline group).
A key issue when analyzing biographies of a number of
subjects is inter-subjects heterogeneity due to unobserved
confounding factors. In our case study, there could be a
number of unobserved factors (such us a patient’s com-
pliance with precriptions and practictioner’s habits) that
could bias the outcome of a statistical analysis that does not
account for possible heterogeneity. One way to investigate
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Age distribution in study sample: males
Figure 2: Age distribution of the 141 males in the study sample.
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Figure 3: Prescription histories of the 82 subjects experiencing cold
symptoms in the study sample, during the follow up (period June
2002 to October 2005).
and accommodate this heterogeneity is to use models that
include random eﬀects. We thereby generalized our analysis
by ﬁtting a Cox model with a random intercept [12]. This
approach allows (i) to adjust risk estimates by unobserved
heterogeneityand,simultaneously,(ii)totestthesigniﬁcance
of the amount of heterogeneity found in the data, through a
Chi-squared test on the variance of the random eﬀect.
3. Results
3.1. Relative Incidence of Costs on the Recurrence of Precrip-
tions. Figure 4 shows the relationship between the relative
incidence of allopathic costs on homeopathic costs and
durations between prescriptions.4 Evidence-Based Complementary and Alternative Medicine
0
100
200
300
400
500
−1.5 −1 −0.5 0 0.5 1 1.5
Allopathic
treatment
Homeopathic
treatment
Prescription rate and relative treatment cost
Cumulative diﬀerence between allopathic and homeopathic costs
I
n
t
e
r
-
p
r
e
s
s
c
r
i
p
t
i
o
n
i
n
t
e
r
v
a
l
(
d
a
y
s
)
Figure 4: Inter-prescription intervals versus the relative cumulative
diﬀerence between allopathic and homeopathic costs.
Table 1: Cox regression of inter-prescriptions durations.
Covariate Exp(coef) Lower 0.95 Upper 0.95
Age at prescription (years) 1.006 1.000 1.012
Male (ref: female) 1.161 0.893 1.511
Allopathic relative incidence 0.817 0.699 0.955
Intervals featuring a pure homeopathic treatment are
on average shorter than intervals characterized by allopathic
prescriptions.Interestingly,thevariabilityofdurationsseems
to increase only when allopathic costs are larger then their
homeopathiccounterpart,reachingamaximumwhenapure
allopathic strategy is undergone. For illustratory purposes, a
comparison between the intervals distribution under a pure
homeopathic and a pure allopathic strategy is shown by
Figure 5: the risk of large intervals between prescriptions is
lower for subjects undergoing homeopathic treatments than
that experienced by subjects under a conventional allopathic
treatment.
3.2. Risks of Precriptions Re-Occurrences. Figure 5 shows
some evidence of the impact that cost incidence seems to
have on the length of the intervals between any two subse-
quent prescriptions, but it does not allow a clear-cut con-
clusion. We hence ﬁtted a Cox proportional hazards model
where the re-occurrences rate is regressed on the relative
diﬀerence between allopathic and homeopathic cumulative
costs,simultaneouslyadjustingfortheavailableconfounding
factors (age and gender). Tests [13]o fh a z a r d sp r o p o r -
tionality were statistically signiﬁcant on each covariate—
P-values: .962 (age), .382 (gender) and .350 (relative cost
incidence). Table 1 reports the resulting estimates of risks
with 95% conﬁdence intervals.
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Figure 5: Cumulative proportions of inter-prescriptions intervals
exhibited by subjects undergoing a pure allopathic strategy (solid
line) and a pure homeopathic strategy (dashed line).
Table 2: Random eﬀect Cox regression of inter-prescriptions
durations.
Covariate Exp(coef) Lower 0.95 Upper 0.95
Age at prescription (years) 1.006 1.000 1.013
Male (ref: female) 1.192 0.874 1.627
Allopathic relative incidence 0.820 0.681 0.987
Remarkably, no signiﬁcant diﬀerences were found
between gender groups. The marginally signiﬁcant eﬀect of
age indicates that the risk of re-occurrence of prescriptions
l a t e ri nt i m em a yi n c r e a s e su pt o1 . 2 %f o re a c hy e a ro f
life, no matter which treatment strategy is chosen. After
adjusting for age and gender, the impact of relative allopathic
cost incidence is still signiﬁcant and the estimate of Table 1
shows that decreasing the relative (economic) incidence of
allopathic drugs by 1%, reduces the risk of prescription re-
occurrences by 18% (±12% at 95% conﬁdence level).
3.3. Accounting for Unobserved Confounding Factors.
Although encouraging, the outcomes reported in Table 1
could be biased in the case of important confounding factors
that were not observed during the present study. In other
words, it is possible that subjects are heterogeneus with
respect to one or more unobserved covariates that could
have a signiﬁcant inﬂuence on the response variable. Table 2
displays the estimates obtained after including a random
eﬀect in the Cox proportional hazards model, to account for
latent heterogeneity.
The estimated variance of the random eﬀect was equal
to .093 (P = .110), suggesting that the subjects in the
study sample were not signiﬁcantly heterogeneous. The
outcomes obtained without the inclusion of a random
eﬀect (Table 1) are essentially conﬁrmed after accounting forEvidence-Based Complementary and Alternative Medicine 5
latent heterogeneity. In particular, the inﬂuence of relative
allopathic cost incidence is still signiﬁcant, although with
a wider conﬁdence interval than that obtained without
including a random eﬀect.
4. Discussion
Studies on cost eﬀectiveness of homeopathy are usually
based on comparing outcomes such as current severity of
symptoms and quality of life indexes between a group of
patients who undergo homeopathic treatment and a group
of subjects treated by conventional medicine. The alternative
approach pursued in this article was based on taking the rate
at which prescriptions occur in a subject as the outcome
of interest, leaving the sampled subjects free to change
treatment strategy during the follow up. We found that the
rate of event occurrences (prescriptions) can be predicted
by the cumulative history of prescription costs experienced
by a subject. Speciﬁcally, patients who favor homeopathy
experience a reduced risk of prescriptions re-occurrence,
compared to those who favor an allopathic pharmacological
strategy.
Caution is however necessary in the interpretation of
this result. First, our results cannot be generalized to
the Italian population, since we considered a cohort of
journalists’ families and the age distribution of the sample
does not emulate that of the Italian population. Secondly,
homeopathy and conventional medicine were in this article
compared according to their costs and, as a result, we assume
that a strategy is favored over the other when a strategy’s cost
is higher than the cost of the alternative strategy. Third, this
research was based on cold symptoms, to collect a reasonable
number of cases in a follow up of 40months, and cannot be
generalized to other types of symptoms. Fourth, our study
did not include the observation of possible confounding
factors such as subjects’ compliance with prescriptions,
practictioners habits, average duration of therapies and daily
therapy costs. We tested our estimates for the presence of
signiﬁcant heterogeneity and we found that our sample is
not signiﬁcantly heterogeneous. However, it is possible that
the homogeneity found in the data is the result of a follow up
of limited length (40months).
Under the assumption that an observed prescription
interval is a marker for cold symptom recurrence, our
analysis would oﬀer evidence that a homeopathic strategy
is associated with a reduced risk of symptoms recurrence.
Althoughthishypothesisislikelyinthepresentcasestudy,we
should not ignore that our analysis is based on prescriptions
whose costs were reimbursed by the insurance company,
hence excluding possible events which were not reported
to the company. Furthermore, our study lacks of data on
medical eﬀectiveness, such as beneﬁts experienced by the
patients, either self-reported or reported by physicians [10,
12]. For these reasons, the hypothesis that nonoccurrence of
new prescriptions in a subject’s history can be interpreted as
nonoccurrence of further symptoms remains an assumption
and cannot be rigorously tested on the basis of the available
data.
Although with these limitations, our analysis shows
evidence that, while total costs of homeopathic and allo-
pathic pharmacological strategies are similar in a history
of cold symptoms, the rate at which prescriptions occurr
raise when allopathic strategies are preferred to homeopathic
alternatives.
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